Nichi-Iko Seeks To Acquire Teikoku Medix To Be Largest Japanese Generic
This article was originally published in PharmAsia News
Executive Summary
Nichi-Iko Pharmaceutical plans to acquire Teikoku Medix, also of Japan, in a bid to become the largest maker of generic drugs in the country. The Nichi-Iko plan is to make the move as early as this summer and turn the Teikoku unit into a wholly owned subsidiary. The value of Teikoku Medix stock, owned by Teikoku Seiyaku, is estimated at about $70 million. The planned merger would combine sales worth $424 million, more than any other generic in Japan. (Click here for more - a subscription may be required
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.